Hikma Pharmaceuticals Public annual free cash flow
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Free Cash Flow (FCF) History (HIK)
Hikma Pharmaceuticals Public reported $239.0M in free cash flow for fiscal 2025, a decrease of 40.10% from the previous fiscal year, with a free cash flow margin of 7.14%.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $239.0M | −$160.0M | −40.10% | +7.14% |
| 2024 | 2024-12-31 | $399.0M | −$40.0M | −9.11% | +12.76% |
| 2023 | 2023-12-31 | $439.0M | $47.0M | +11.99% | +15.27% |
| 2022 | 2022-12-31 | $392.0M | −$101.0M | −20.49% | +15.57% |
| 2021 | 2021-12-31 | $493.0M | $201.0M | +68.84% | +19.31% |
| 2020 | 2020-12-31 | $292.0M | — | — | +12.47% |
Hikma Pharmaceuticals Public free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $292.0M to $239.0M, a compound annual decline of 3.93%.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...